auto-injectors for glp-1 delivery DELIVERING ON DEMAND: A COMBINATION OF DEVICE OFFERINGS AND SUPPLY STRATEGY What to do if you

This triagonism distinguishes it from existing therapies such as semaglutide and tirzepatide, which focus on single or dual receptor pathways

The lack of immunogenicity has practical implications: the peptide can be used for extended periods without loss of efficacy due to antibody neutralization, there is minimal risk of allergic or hypersensitivity reactions, and repeated treatment cycles are supported as prior exposure does not sensitize the immune system

The 2024 FDA approval of resmetirom, the first targeted therapy for MASLD/MASH, represents a significant advancement (88)

In diabetics, a single local injection can temporarily raise blood sugar